PRA (CRD3) Testing for Glen of Imaal Terrier Vision Health
Progressive retinal atrophy (PRA) is a hereditary eye disorder causing gradual deterioration of the retina, leading to blindness in affected dogs over time. The CRD3 type of PRA, called cone-rod dystrophy 3, primarily impacts the Glen of Imaal Terrier breed, making genetic testing for this condition essential for responsible breeding and pet care in the U.S.
This disease stems from a mutation in the ADAM9 gene and is inherited in an autosomal recessive pattern. Simply put, a dog must inherit two mutated gene copies (one from each parent) to develop PRA (CRD3), while carriers with a single copy remain symptom-free but can pass the mutation along to their pups.
What Is PRA (CRD3) Progressive Retinal Atrophy?
PRA (CRD3) involves progressive degeneration of the retina’s cone cells responsible for daytime vision, followed by rod cells that support low-light and night vision. This deterioration initially causes challenges seeing in both bright and dim lighting and eventually results in blindness over several years.
Which Dogs Are Susceptible to PRA (CRD3)?
This particular form of PRA is mostly found in Glen of Imaal Terrier puppies and their mixed breeds carrying Glen genes. Because of its breed-specific nature, it’s vital for breeders and owners of dogs with Glen heritage to pursue testing to prevent spreading this condition within the bloodline.
Symptoms and Early Warning Signs
Puppies and young dogs under age three usually show no outward signs even as the disease starts progressing between 12 and 24 months. Early symptoms may include difficulty navigating in low light or unfamiliar settings. As vision worsens, dogs lose sharpness of sight, culminating in full blindness.
Understanding PRA (CRD3) Inheritance
PRA (CRD3) passes on through autosomal recessive inheritance, meaning dogs need two mutated gene copies to be affected. Those with only one mutated gene are healthy carriers but can pass the mutation to their offspring. Responsible breeding involves careful pairing to avoid producing affected puppies.
Genetic Testing Procedure
To test for PRA (CRD3), a DNA sample is collected by cheek swab or small blood draw. This sample is sent to an accredited veterinary genetic lab, with results usually available within one to two weeks.
Your local American veterinarian can collect the sample and typically handles submitting it to the testing facility. In the U.S., labs like Paw Print Genetics and Wisdom Panel provide this genetic screening aimed at determining if a dog is clear, a carrier, or affected by the mutation.
Why Testing is Vital for Responsible Breeding and Ownership
Testing breeding Glen of Imaal Terriers and dogs with Glen ancestry helps breeders avoid mating two carriers or affected dogs, significantly reducing PRA cases over time. For pet owners not involved in breeding, knowing your dog's genetic status is valuable for anticipating future health needs and managing care accordingly.
By committing to health testing, breeders and owners support the welfare and lifespan of this rare breed, helping maintain healthy populations and preventing avoidable suffering from blindness.
Steps to Take for PRA (CRD3) Testing
- Consult your American veterinarian to arrange a DNA test for PRA (CRD3) in your Glen of Imaal Terrier or dog with Glen background.
- Provide a cheek swab or a blood sample for the test.
- Wait for lab results that will classify your dog as clear, a carrier, or affected.
- Use these results to guide responsible breeding choices or care management.
Adopting these informed health testing practices not only promotes healthier litters but also improves quality of life for dogs potentially carrying this genetic eye disease.
